vandetanib + omeprazole + ranitidine
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Medullary Thyroid Cancer
Conditions
Medullary Thyroid Cancer
Trial Timeline
Feb 1, 2012 → Sep 1, 2012
NCT ID
NCT01539655About vandetanib + omeprazole + ranitidine
vandetanib + omeprazole + ranitidine is a phase 1 stage product being developed by Sanofi for Medullary Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT01539655. Target conditions include Medullary Thyroid Cancer.
What happened to similar drugs?
1 of 4 similar drugs in Medullary Thyroid Cancer were approved
Approved (1) Terminated (1) Active (2)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01539655 | Phase 1 | Completed |
Competing Products
9 competing products in Medullary Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Selpercatinib + Cabozantinib + Vandetanib | Eli Lilly | Phase 3 | 44 |
| Selpercatinib | Eli Lilly | Phase 1/2 | 36 |
| Pralsetinib + Cabozantinib + Vandetanib | Roche | Phase 3 | 32 |
| • TF2 and 68 Ga-IMP-288 | Gilead Sciences | Phase 1/2 | 32 |
| Caprelsa | Sanofi | Pre-clinical | 26 |
| Vandetanib 300mg | Sanofi | Phase 1/2 | 32 |
| Vandetanib | Sanofi | Phase 3 | 40 |
| Cabozantinib (XL184) 140 mg + Cabozantinib (XL184) 60 mg + Placebo tablet + Placebo capsule | Exelixis | Approved | 44 |
| cabozantinib | Exelixis | Pre-clinical | 23 |